Bogart Wealth LLC Sells 3,092 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bogart Wealth LLC lessened its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 13.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,167 shares of the pharmaceutical company's stock after selling 3,092 shares during the quarter. Bogart Wealth LLC's holdings in Vertex Pharmaceuticals were worth $9,293,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Quent Capital LLC boosted its holdings in Vertex Pharmaceuticals by 4.5% during the first quarter. Quent Capital LLC now owns 513 shares of the pharmaceutical company's stock worth $249,000 after buying an additional 22 shares in the last quarter. Sculati Wealth Management LLC lifted its holdings in Vertex Pharmaceuticals by 1.0% during the fourth quarter. Sculati Wealth Management LLC now owns 2,556 shares of the pharmaceutical company's stock valued at $1,029,000 after purchasing an additional 25 shares in the last quarter. Avidian Wealth Enterprises LLC lifted its holdings in Vertex Pharmaceuticals by 2.1% during the first quarter. Avidian Wealth Enterprises LLC now owns 1,225 shares of the pharmaceutical company's stock valued at $594,000 after purchasing an additional 25 shares in the last quarter. Strategic Blueprint LLC lifted its holdings in Vertex Pharmaceuticals by 1.7% during the first quarter. Strategic Blueprint LLC now owns 1,498 shares of the pharmaceutical company's stock valued at $726,000 after purchasing an additional 25 shares in the last quarter. Finally, Breakwater Capital Group raised its position in shares of Vertex Pharmaceuticals by 1.5% in the first quarter. Breakwater Capital Group now owns 1,786 shares of the pharmaceutical company's stock valued at $866,000 after buying an additional 27 shares during the last quarter. Institutional investors own 90.96% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Royal Bank Of Canada set a $420.00 target price on shares of Vertex Pharmaceuticals and gave the company a "sector perform" rating in a research report on Tuesday, June 17th. Needham & Company LLC restated a "hold" rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Erste Group Bank lowered shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 23rd. Finally, Leerink Partners reiterated a "market perform" rating and issued a $503.00 price target (down previously from $550.00) on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 6th. Fourteen investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $511.62.

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $468.85 on Monday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.29 and a current ratio of 2.65. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a market cap of $120.40 billion, a P/E ratio of -119.60 and a beta of 0.41. The business's fifty day moving average is $447.71 and its two-hundred day moving average is $461.11.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23). The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.85 billion. Vertex Pharmaceuticals had a negative return on equity of 3.36% and a negative net margin of 8.91%. The firm's revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the company earned $4.76 earnings per share. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.